Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08 Article

Wen, Patrick Y, Yung, WK Alfred, Lamborn, Kathleen R et al. (2006). Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08 . CLINICAL CANCER RESEARCH, 12(16), 4899-4907. 10.1158/1078-0432.CCR-06-0773

Industry Collaboration

cited authors

  • Wen, Patrick Y; Yung, WK Alfred; Lamborn, Kathleen R; Dahia, Patricia L; Wang, Yanfeng; Peng, Bin; Abrey, Lauren E; Raizer, Jeffrey; Cloughesy, Timothy F; Fink, Karen; Gilbert, Mark; Chang, Susan; Junck, Larry; Schiff, David; Lieberman, Frank; Fine, Howard A; Mehta, Minesh; Robins, H Ian; DeAngelis, Lisa M; Groves, Morris D; Puduvalli, Vinay K; Levin, Victor; Conrad, Charles; Maher, Elizabeth A; Aldape, Kenneth; Hayes, Michael; Letvak, Laurie; Egorin, Merrill J; Capdeville, Renaud; Kaplan, Richard; Murgo, Anthony J; Stiles, Charles; Prados, Michael D

sustainable development goals

authors

publication date

  • August 15, 2006

webpage

published in

keywords

  • CELL-GROWTH
  • DRUG
  • GLIOBLASTOMA
  • GROWTH-FACTOR EXPRESSION
  • HUMAN ASTROCYTOMAS
  • HUMAN MENINGIOMAS
  • KINASE INHIBITOR
  • Life Sciences & Biomedicine
  • Oncology
  • PDGF-RECEPTOR GENES
  • Science & Technology
  • TRANSFORMED PHENOTYPE
  • TYROSINE KINASE

Digital Object Identifier (DOI)

publisher

  • AMER ASSOC CANCER RESEARCH

start page

  • 4899

end page

  • 4907

volume

  • 12

issue

  • 16